Translate this page into:
Clinical significance of thymidine kinase in Egyptian children with acute lymphoblastic leukemia
*Corresponding author: Prof. Adel A. Hagag. adelhagag20@yahoo.com
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
Abstract
Abstract
Background: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, representing one-third of pediatric cancers. Thymidine kinase-1 (TK-1) is expressed in proliferating cells so elevated TK-1 indicates active tumor growth. Objective: To study the clinical significance of TK-1 in children with ALL. Patients and Methods: This study was carried out on 40 children with newly diagnosed ALL who were admitted to Oncology Unit, Pediatric department, Tanta University (26 males and 14 females) with their ages ranged from 4 to 10 years and 30 healthy children of matched age and sex as a control group. For all patients the following were done: Complete blood picture, bone marrow examination, immunophenotyping and TK-1 serum levels. Results: Mean TK-1 level was significantly higher in patients at diagnosis than controls and significantly higher in patients with unfavorable outcome than patients with favorable outcome. Mean TK-1 level was significantly higher in patients in relapse than patients in remission and controls. No significant differences in mean TK-1 level between patients in remission and controls. There were statistically significant differences in disease free survival and overall survival between patients with favorable and unfavorable outcome. Conclusion: From this study we concluded that TK is a helpful marker in diagnosis and follow-up of patients with ALL. Recommendations: Thymidine kinase-1 should be routinely assessed at diagnosis and during follow-up in ALL patients for better diagnostic and prognostic assessment and should be taken in consideration in designing future therapeutic strategies based on patients-specific risk factors.
Keywords
References
- Ribera JM, Oriol A. Acute lymphoblastic leukemia in adolescents and young adults. Hematol Oncol Clin North Am 2009;23:1033-42, vi.
- Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-78.
- Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: A report from the children′s oncology group. J Clin Oncol 2012;30:1663-9.
- Wu C, Yang R, Zhou J, Bao S, Zou L, Zhang P, et al. Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods 2003;277:157-69.
- O′Neill KL, Zhang F, Li H, Fuja DG, Murray BK. Thymidine kinase 1 - A prognostic and diagnostic indicator in ALL and AML patients. Leukemia 2007;21:560-3.
- Catovsky D, Hoffbrand AV. Acute myeloid leukaemia. In: Hoffbrand AV, Lewis SM, editors. Postgraduate Haematology. 5 th ed., London, UK: Royal Free Hospital Reed Educational and Professional Publishing Ltd.; 2005. p. 509-24.
- Ching-Hon Pui. Acute lymphoplastic leukemia: Overview. In: Lichtman MA, Beulter E, Seligsonn U, Kipps TO, Kaushansky K, Prchal J, editors. William Textbook of Hematology. 17 th ed., Ch. 91. New York: McGraw-Hill Companies, Inc.; 2007. p. 1141-53.
- Zhang F, Shao X, Li H, Robison JG, Murray BK, O′Neill KL. A monoclonal antibody specific for human thymidine kinase 1. Hybridoma 2001;20:25-34.
- Tubergen DG, Bleyer A. The leukemias. In: Behrman RE, Kliegman RM, Jenson HB, editors. Nelson Textbook of Pediatrics. 18 th ed. Philadelphia, USA: John F Kennedy Blvd. Copyright 2007 by Saunders an imprint of Elsevier Inc.; 2007. p. 2116-2.
- Lanzkowsky PH. Leukemias. In: Philip L, editor. Manual of Pediatric Hematology and Oncology. 4 th ed., Vol. 17. Nek, London, Madrid: Churchill Livingstone; 2011. p. 518-66.
- Hagag AA, Nosair NA, Ghaith FM, Elshenawy EH. Prognostic value of protease activated receptor-1 in children with acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis 2014;6:e2014029.
- Biswas S, Chakrabarti S, Chakraborty J, Paul PC, Konar A, Das S. Childhood acute leukemia in West Bengal, India with an emphasis on uncommon clinical features. Asian Pac J Cancer Prev 2009;10:903-6.
- Ahmed MI, Hassab HM. Study of soluble CD44 and its expression by mononuclear cells in children with acute lymphoblastic leukemia: Its relation to prognostic factors. Egypt J Immunol 2008;15:101-11.
- Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M, et al. Treatment outcome and prognostic factors for infants with ALL. J Clin Oncol 2009;114:3764-8.
- Votava T, Topolcan O, Holubec L JR , Cerna Z, Sasek L, Finek J, et al. Changes of serum thymidine kinase in children with acute leukemia. Anticancer Res 2007;27:1925-8.
- Konoplev SN, Fritsche HA, O′Brien S, Wierda WG, Keating MJ, Gornet TG, et al. High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. Am J Clin Pathol 2010;134:472-7.
- Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN, et al. Long-term results of the children′s cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: A Children′s Oncology Group Report. Leukemia 2010;24:285-97.